Signaling-specific inhibition of the CB(1) receptor for cannabis use disorder: phase 1 and phase 2a randomized trials

Cannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB(1)-SSi). AEF0117 selectively inhibits a subset of intracellular effects resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Haney, Margaret, Vallée, Monique, Fabre, Sandy, Collins Reed, Stephanie, Zanese, Marion, Campistron, Ghislaine, Arout, Caroline A., Foltin, Richard W., Cooper, Ziva D., Kearney-Ramos, Tonisha, Metna, Mathilde, Justinova, Zuzana, Schindler, Charles, Hebert-Chatelain, Etienne, Bellocchio, Luigi, Cathala, Adeline, Bari, Andrea, Serrat, Roman, Finlay, David B., Caraci, Filippo, Redon, Bastien, Martín-García, Elena, Busquets-Garcia, Arnau, Matias, Isabelle, Levin, Frances R., Felpin, François-Xavier, Simon, Nicolas, Cota, Daniela, Spampinato, Umberto, Maldonado, Rafael, Shaham, Yavin, Glass, Michelle, Thomsen, Lars Lykke, Mengel, Helle, Marsicano, Giovanni, Monlezun, Stéphanie, Revest, Jean-Michel, Piazza, Pier Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287566/
https://www.ncbi.nlm.nih.gov/pubmed/37291212
http://dx.doi.org/10.1038/s41591-023-02381-w

Ejemplares similares

Ejemplares similares